Identification of genetically-supported new drug targets for osteomyelitis based on druggable genomes.

ABSTRACT:

Background

Limited drug treatment data are available for osteomyelitis (OM), an inflammatory bone condition secondary to infection. Given its genetic characteristics, it is necessary to integrate genetics into drug development for osteomyelitis. This study applied pharmacogenomics to identify new drug targets for osteomyelitis using Mendelian randomization (MR).

Methods

Following the Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization guidelines, expression and protein quantitative trait loci (QTL) analysis was applied to simulate drug exposure. Single nucleotide polymorphisms were selected as instrumental variables for MR analysis using blood QTL data and independent osteomyelitis genome-wide association study datasets from UK

SUBMITTER: Yao R 

PROVIDER: S-EPMC12505852 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature